Current Cardiology Reports

, 20:8 | Cite as

Heart Failure Interventions Targeting Impaired Left Ventricles in Structural Heart Disease

  • Mitsunobu Kitamura
  • Tobias Schmidt
  • Karl-Heinz Kuck
  • Christian Frerker
Structural Heart Disease (RJ Siegel and NC Wunderlich, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Structural Heart Disease


Purpose of Review

Interventional techniques have been developed for a wide spectrum of mechanisms of heart failure (HF), especially in valvular heart disease and cardiomyopathies (ischaemic cardiomyopathy and hypertrophic cardiomyopathy). In this article, we review recent reports on catheter interventions to treat patients with HF.

Recent Findings

Direct modification using the Parachute device and the REVIVENT-TC device for patients with impaired left ventricle with large infarct scars improves geometry and haemodynamic efficiency, resulting in a reduction of HF symptoms. Interatrial shunt therapy improves symptoms and quality of life in HF patients. Uniquely, left ventricular outflow tract obstruction has also been targeted in patients with transcatheter mitral valve implantation.


For advanced stage HF patients with prohibitively high surgical risk, emerging transcatheter interventions make it possible to modify life-limiting symptoms. Further results on HF interventions are expected from ongoing clinical trials.


Heart failure interventions Ischaemic cardiomyopathy Left ventricular reconstruction Interatrial shunt device Left ventricular outflow tract obstruction 


Compliance with Ethical Standards

Conflict of Interest

Mitsunobu Kitamura, Karl-Heinz Kuck, and Christian Frerker declare that they have no conflict of interest. Tobias Schmidt receives lecture honoraria from CardioKinetix and Bioventrix.

Human and Animal Rights and Informed Consent

This article is a review and contains studies of humans in which we participated. These were the PARACHUTE III and V, the Bioventrix studies and the Mitraclip procedure in HOCM patients. All patients signed a patient informed consent form.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Bolognese L, Neskovic AN, Parodi G, Cerisano G, Buonamici P, Santoro GM, et al. Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation. 2002;106(18):2351–7. Scholar
  2. 2.
    Savoye C, Equine O, Tricot O, Nugue O, Segrestin B, Sautiere K, et al. Left ventricular remodeling after anterior wall acute myocardial infarction in modern clinical practice (from the REmodelage VEntriculaire [REVE] study group). Am J Cardiol. 2006;98(9):1144–9. Scholar
  3. 3.
    •• Costa MA, Mazzaferri EL Jr, Sievert H, Abraham WT. Percutaneous ventricular restoration using the parachute device in patients with ischemic heart failure: three-year outcomes of the PARACHUTE first-in-human study. Circ Heart Fail. 2014;7(5):752–8. This is the first human study of a parachute device. CrossRefPubMedGoogle Scholar
  4. 4.
    •• Thomas M, Nienaber CA, Ince H, Erglis A, Vukcevic V, Schafer U, et al. Percutaneous ventricular restoration (PVR) therapy using the parachute device in 100 subjects with ischaemic dilated heart failure: one-year primary endpoint results of PARACHUTE III, a European trial. EuroIntervention. 2015;11(6):710–7. This report provides the results from the largest multicenter study of parachute device. CrossRefPubMedGoogle Scholar
  5. 5.
    Del Trigo M, Bergeron S, Bernier M, Amat-Santos IJ, Puri R, Campelo-Parada F, et al. Unidirectional left-to-right interatrial shunting for treatment of patients with heart failure with reduced ejection fraction: a safety and proof-of-principle cohort study. Lancet. 2016;387(10025):1290–7. Scholar
  6. 6.
    • Schmidt T, Frerker C, Thielsen T, Dotz I, Wohlmuth P, Kuck KH, et al. New evidence for favourable effects on haemodynamics and ventricular performance after parachute((R)) implantation in humans. Eur J Heart Fail. 2014;16(10):1112–9. This study descrives the effects of parachute device implantation on haemodynamics. CrossRefPubMedGoogle Scholar
  7. 7.
    Schäfer U, Lubos E, Deuschl F, Schofer N, Grahn H, Conradi L, et al. Transseptal and transmitral parachute(R) implantation in conjunction with “MitraClipping”. EuroIntervention. 2015;11(6):673–81. Scholar
  8. 8.
    Costa MA, Pencina M, Nikolic S, Engels T, Templin B, Abraham WT. The PARACHUTE IV trial design and rationale: percutaneous ventricular restoration using the parachute device in patients with ischemic heart failure and dilated left ventricles. Am Heart J. 2013;165(4):531–6. Scholar
  9. 9.
    Cooley DA. Ventricular endoaneurysmorrhaphy: a simplified repair for extensive postinfarction aneurysm. J Card Surg. 1989;4(3):200–5. Scholar
  10. 10.
    Dor V, Saab M, Coste P, Kornaszewska M, Montiglio F. Left ventricular aneurysm: a new surgical approach. Thorac Cardiovasc Surg. 1989;37(1):11–9. Scholar
  11. 11.
    Athanasuleas CL, Stanley AW Jr, Buckberg GD, Dor V, DiDonato M, Blackstone EH. Surgical anterior ventricular endocardial restoration (SAVER) in the dilated remodeled ventricle after anterior myocardial infarction. RESTORE group Reconstructive Endoventricular Surgery, returning Torsion Original Radius Elliptical Shape to the LV. J Am Coll Cardiol. 2001;37(5):1199–209.CrossRefPubMedGoogle Scholar
  12. 12.
    Jones RH, Velazquez EJ, Michler RE, Sopko G, Oh JK, O'Connor CM, et al. Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med. 2009;360(17):1705–17. Scholar
  13. 13.
    Yamaguchi A, Adachi H, Kawahito K, Murata S, Ino T. Left ventricular reconstruction benefits patients with dilated ischemic cardiomyopathy. Ann Thorac Surg. 2005;79(2):456–61. Scholar
  14. 14.
    Athanasuleas CL, Buckberg GD, Stanley AW, Siler W, Dor V, DiDonato M, et al. Surgical ventricular restoration: the RESTORE group experience. Heart Fail Rev. 2004;9(4):287–97. Scholar
  15. 15.
    Michler RE, Rouleau JL, Al-Khalidi HR, Bonow RO, Pellikka PA, Pohost GM, et al. Insights from the STICH trial: change in left ventricular size after coronary artery bypass grafting with and without surgical ventricular reconstruction. J Thorac Cardiovasc Surg. 2013;146(5):1139–45 e6. Scholar
  16. 16.
    •• Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. ESC/EACTS guidelines on myocardial revascularization. EuroIntervention. 2014;10(9):1024–94. This is the current ESC/EACTS guideline for myocardial revascularization. CrossRefGoogle Scholar
  17. 17.
    •• Wechsler AS, Sadowski J, Kapelak B, Bartus K, Kalinauskas G, Rucinskas K, et al. Durability of epicardial ventricular restoration without ventriculotomy. Eur J Cardiothorac Surg. 2013;44(3):e189–92. discussion e92. This is the first report of epicardial ventricular restoration using the Revivent device. CrossRefPubMedGoogle Scholar
  18. 18.
    Heeger CH, Frerker C, Hayashi K, Schmidt T, Mathew S, Sohns C, et al. Catheter ablation of frequent ventricular tachycardia after interventional left ventricular restoration with the revivent-transcatheter(TM)-system. Clin Case Rep. 2016;4(4):339–43. Scholar
  19. 19.
    Observational study to collect data on health improvements after mini-invasive operation with Revivent TC device to reshape the heart and reduce its volume: BioVentrix Registry Assessment of Ventricular Enhancement for the Revivent TC system (BRAVE-TC)., 2016; URL
  20. 20.
    Sondergaard L, Reddy V, Kaye D, Malek F, Walton A, Mates M, et al. Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure. Eur J Heart Fail. 2014;16(7):796–801. Scholar
  21. 21.
    Malek F, Neuzil P, Gustafsson F, Kaye DM, Walton A, Mates M, et al. Clinical outcome of transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel implant. Int J Cardiol. 2015;187:227–8. Scholar
  22. 22.
    Feldman T, Komtebedde J, Burkhoff D, Massaro J, Maurer MS, Leon MB, et al. Transcatheter interatrial shunt device for the treatment of heart failure: rationale and design of the randomized trial to REDUCE elevated left atrial pressure in heart failure (REDUCE LAP-HF I). Circ Heart Fail. 2016;9(7):e003025. Scholar
  23. 23.
    Hasenfuss G, Hayward C, Burkhoff D, Silvestry FE, McKenzie S, Gustafsson F, et al. A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial. Lancet. 2016;387(10025):1298–304. Scholar
  24. 24.
    Kaye DM, Hasenfuss G, Neuzil P, Post MC, Doughty R, Trochu JN, et al. One-year outcomes after transcatheter insertion of an interatrial shunt device for the management of heart failure with preserved ejection fraction. Circ Heart Fail. 2016;9(12):e003662.
  25. 25.
    Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 1995;346(8969):211–4. Scholar
  26. 26.
    •• Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733–79. This is the current ESC guideline for hypertrophic cardiomyopathy. CrossRefPubMedGoogle Scholar
  27. 27.
    •• Veselka J, Jensen MK, Liebregts M, Januska J, Krejci J, Bartel T, et al. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry. Eur Heart J. 2016;37(19):1517–23. This is the first report from the Euro-ASA registry, the largest multinational study cohort. CrossRefPubMedGoogle Scholar
  28. 28.
    • Veselka J, Faber L, Liebregts M, Cooper R, Januska J, Krejci J, et al. Outcome of alcohol septal ablation in mildly symptomatic patients with hypertrophic obstructive cardiomyopathy: a long-term follow-up study based on the euro-alcohol septal ablation registry. J Am Heart Assoc. 2017;6(5). This report describes the results of alcohol septal ablation in mildly symptomatic patients with hypertrophic obstructive cardiomyopathy.
  29. 29.
    • Liebregts M, Faber L, Jensen MK, Vriesendorp PA, Januska J, Krejci J, et al. Outcomes of alcohol septal ablation in younger patients with obstructive hypertrophic cardiomyopathy. JACC Cardiovasc Interv. 2017;10(11):1134–43. This report describes the results of alcohol septal ablation in younger patients with hypertrophic obstructive cardiomyopathy. CrossRefPubMedGoogle Scholar
  30. 30.
    • Schäfer U, Kreidel F, Frerker C. MitraClip implantation as a new treatment strategy against systolic anterior motion-induced outflow tract obstruction in hypertrophic obstructive cardiomyopathy. Heart Lung Circ. 2014;23(5):e131–5. This is the first report of MitraClip® therapy for hypertrophic obstructive cardiomyopathy. CrossRefPubMedGoogle Scholar
  31. 31.
    Schäfer U, Frerker C, Thielsen T, Schewel D, Bader R, Kuck KH, et al. Targeting systolic anterior motion and left ventricular outflow tract obstruction in hypertrophic obstructed cardiomyopathy with a MitraClip. EuroIntervention. 2015;11(8):942–7. Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Mitsunobu Kitamura
    • 1
  • Tobias Schmidt
    • 1
  • Karl-Heinz Kuck
    • 1
  • Christian Frerker
    • 1
  1. 1.Department of CardiologyAsklepios Klinik St. GeorgHamburgGermany

Personalised recommendations